The Brazilian health regulator has announced that clinical trials of the Chinese-developed Kovid-19 vaccine have been halted following an adverse event involving a volunteer.
Coronavac, developed by Chinese pharmaceutical company Sinovac Biotech, has suffered a setback. US pharmaceutical giant Pfizer announced yesterday that its own vaccine candidate has shown 90% effectiveness., Boosting global markets and raising hopes of an end to the epidemic.
The Brazilian regulator said in a statement on October 29 that it had ruled in favor of interrupting the clinical study of the corona vaccine.
Privacy rules do not provide details about what happened, but such cases include death, fatal side effects, serious disability, hospitalization, birth defects, and other “clinically significant events.”
However, the Butentan Institute, a public health center that coordinates vaccine trials in Brazil, said it was surprised by the decision.
The institute is investigating in detail what happened, and the Brazilian regulatory agency has the clue to provide the necessary clarity on any adverse event that clinical trials may present.
It was announced that a press conference will be held this evening.
Coronawalk is embroiled in a tumultuous political struggle in Brazil, where the most supportive is Sao Paulo Governor Joao Doria, a leading rival of far-right President Jair Bolsonaro.
The Sao Paulo state government said in a statement that it was “sorry to hear of this decision from the press directly from Anvisa” and was waiting with the Button Institute for more information on the “real reasons for the suspension”.
The Bolsonaro coronavac vaccine is labeled “from other countries” and is replaced by a competitor vaccine developed by Oxford University and the pharmaceutical company AstraZeneca.
Last month, he fired his own health minister’s plan to buy 46 million doses of coronavac, referring to “Joao Doria’s Chinese vaccine” saying “the Brazilian people will not be anyone’s guinea pig”.
Earlier yesterday, Doria announced that the first 120,000 doses of Coronavirus would arrive in Sao Paulo on November 20.
His state has a contract with Sinovac to buy a total of 46 million doses – six million in China and the rest in Sao Paulo, which collapsed last week to make the vaccine domestically at a factory.
“State government officials fear that Bolsonaro will use technical decisions to delay the vaccine’s timeline for political reasons,” the newspaper Folha de S സo Paulo reported, citing unnamed Doria allies.
Anvisa told AFP that it had no comment beyond announcing the suspension, adding that it was normal practice to suspend trials in such cases.